Cowen And Company, LLC Pro Qr Therapeutics N.V. Transaction History

Cowen And Company, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$0.56 - $1.0 $211,554 - $377,776	-377,776 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $1.07 Million - $9.96 Million	-1,187,068 Reduced 75.86%	377,776 $342,000
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $8.54 Million - $11 Million	1,298,183 Added 486.83%	1,564,844 $12.5 Million
Q2 2021 Aug 13, 2021	SELL	$5.75 - $7.59 $109,451 - $144,475	-19,035 Reduced 6.66%	266,661 $1.8 Million
Q4 2020 Feb 08, 2021	SELL	$3.58 - $4.85 $44,127 - $59,781	-12,326 Reduced 4.14%	285,696 $1.2 Million
Q3 2020 Nov 03, 2020	SELL	$4.79 - $6.3 $9,675 - $12,726	-2,020 Reduced 0.67%	298,022 $1.43 Million
Q2 2020 Aug 13, 2020	SELL	$4.5 - $6.53 $246,631 - $357,889	-54,807 Reduced 15.45%	300,042 $1.82 Million
Q1 2020 May 11, 2020	BUY	$5.25 - $9.9 $1.32 Million - $2.49 Million	251,122 Added 242.1%	354,849 $1.95 Million
Q4 2019 Feb 11, 2020	BUY	$5.84 - $10.51 $605,765 - $1.09 Million	103,727 New	103,727 $1.03 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $285M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.